August 12, 2020 21:20 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
India registers highest single day recoveries of 56,110 | Militant arrested in north Kashmir's Bandipora | Bengaluru: Violence breaks out over alleged social media post, key accused arrested | Pulwama encounter: Soldier, militant killed | India reports over 60,000 Covid-19 cases in 24 hours, tally crosses 2.32 million
Cipla receives final approval for generic version of Shire's Firazyr

Cipla receives final approval for generic version of Shire's Firazyr

India Blooms News Service | @indiablooms | 14 Jul 2020, 04:09 pm

Mumbai/UNI:  Pharma major Cipla on Tuesday said that it has received final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA).

Cipla's Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire's Firazyr.

Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

According to IQVIA (IMS Health), Firazyr and its generic equivalents had US sales of approximately USD270M for the 12-month period ending May 2020. 

 

Related Images
Kolkata witnesses 'supermoon' 01 Jan 1970, 05:30 am
Related Videos
Covid-19 press briefing by WHO 01 Jan 1970, 05:30 am
Covid-19 press briefing in India 01 Jan 1970, 05:30 am